Gopal Purva, Lu Pengcheng, Ayers Gregory D, Herline Alan J, Washington Mary K
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Department of Biostatistics, Division of Cancer Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Mod Pathol. 2014 Sep;27(9):1281-7. doi: 10.1038/modpathol.2013.239. Epub 2014 Jan 17.
Although tumor deposits have been associated with poor prognosis in colorectal carcinoma, the prevalence and clinical significance of tumor deposits in rectal adenocarcinoma following neoadjuvant chemoradiation are relatively unexplored. The aims of this study are to assess the clinical significance of tumor deposits in rectal adenocarcinoma patients, including those receiving neoadjuvant therapy. Pathology slides and medical records from 205 consecutive patients who underwent resection for rectal adenocarcinoma between 1990 and 2010 at a single tertiary care center were reviewed. Patients with tumor deposits had higher tumor grade (P=0.006) and worse tumor stage (P<0.001) at presentation than patients without tumor deposits. Among 110 patients who underwent neoadjuvant chemoradiation, tumor deposits were associated with higher rates of lymph node involvement (P=0.035) and distant metastases (P=0.006), and decreased survival (P=0.027). These patients had a trend toward lower treatment response scores (P=0.285) and higher local recurrence (P=0.092). Of 52 patients with tumor deposits, those who underwent neoadjuvant chemoradiation had significantly worse pretreatment stage by endoscopic ultrasound (P<0.001) but interestingly had significantly lower rates of lymphovascular invasion on resection (P<0.001) compared with those who had not received neoadjuvant chemoradiation. Despite treatment with neoadjuvant chemoradiation, tumor deposits were present in over one-fifth of rectal adenocarcinoma patients. Overall, the outcome of patients with tumor deposits in treated and untreated patients were similar, however the association of tumor deposits with deeply invasive tumors and less tumor regression when comparing with treated patients without tumor deposits raises the possibility that these tumors could have a more aggressive biology, possibly explaining the association of tumor deposits with higher rates of recurrence and lower survival after neoadjuvant chemoradiation. Overall, tumor deposits appear to be a poor prognostic marker among rectal adenocarcinoma patients following neoadjuvant chemoradiation and may identify a subset of patients who require aggressive adjuvant therapy to prevent recurrence.
尽管肿瘤沉积物与结直肠癌的预后不良相关,但新辅助放化疗后直肠腺癌中肿瘤沉积物的发生率及其临床意义尚未得到充分研究。本研究的目的是评估直肠腺癌患者(包括接受新辅助治疗的患者)中肿瘤沉积物的临床意义。回顾了1990年至2010年间在一家三级医疗中心连续接受直肠腺癌切除术的205例患者的病理切片和病历。有肿瘤沉积物的患者在就诊时的肿瘤分级更高(P = 0.006),肿瘤分期更差(P < 0.001)。在110例接受新辅助放化疗的患者中,肿瘤沉积物与更高的淋巴结受累率(P = 0.035)和远处转移率(P = 0.006)相关,且生存率降低(P = 0.027)。这些患者的治疗反应评分有降低趋势(P = 0.285),局部复发率更高(P = 0.092)。在52例有肿瘤沉积物的患者中,接受新辅助放化疗的患者经内镜超声检查的术前分期明显更差(P < 0.001),但有趣的是,与未接受新辅助放化疗的患者相比,其切除时的淋巴管侵犯率明显更低(P < 0.001)。尽管接受了新辅助放化疗,但超过五分之一的直肠腺癌患者仍存在肿瘤沉积物。总体而言,有肿瘤沉积物的患者在接受治疗和未接受治疗时的结果相似,然而,与没有肿瘤沉积物的接受治疗患者相比,肿瘤沉积物与深度浸润性肿瘤以及肿瘤退缩较少相关,这增加了这些肿瘤可能具有更具侵袭性生物学行为的可能性,这可能解释了新辅助放化疗后肿瘤沉积物与更高复发率和更低生存率之间的关联。总体而言,肿瘤沉积物似乎是新辅助放化疗后直肠腺癌患者的一个不良预后标志物,可能识别出一部分需要积极辅助治疗以预防复发的患者。